جميع الدراسات
التوظيفالمرحلة 1، المرحلة 2تدخلي

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

This research study, called NAPISTAR 1-01, is looking into a new treatment named TUB-040 for people with specific types of ovarian cancer and non-small cell lung cancer that have either come back or not responded to usual treatments. TUB-040 is a special drug designed to target cancer cells more directly. The main goals are to find out if TUB-040 is safe, how well the body processes it, and if it can help improve the condition. The study will start by giving increasing doses to find the highest safe dose, and then compare different doses to see which one works best. Participants will receive TUB-040 through a drip every three weeks until their cancer gets worse or side effects become too strong.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 1، المرحلة 2
الراعي
علوم جلعاد
الهدف من التسجيل
334
ابدأ
12 يونيو 2024
التاريخ المتوقع للانتهاء
01 ديسمبر 2027

ما هو موضوع هذه الدراسة؟

This study is a clinical trial, which means it's a carefully planned research study to test a new treatment for people with specific health conditions. Here, the treatment is called TUB-040. We're looking at adults who have been diagnosed with ovarian cancer or a type of lung cancer called non-small cell lung cancer, and for whom standard treatments haven't been as effective as hoped, or their cancer has come back. The main aim is to understand if TUB-040 is a safe treatment, how the body handles it, and if it can help to shrink or control the cancer.

TUB-040 is a clever type of drug. Think of it like a sniffer dog that's been trained to find specific cancer cells. It's called an "antibody-drug conjugate." This means it's made up of two parts: one part (the antibody) is designed to stick to a specific marker (called NaPi2b) that is often found on the surface of some cancer cells, and the other part is a powerful anti-cancer medicine that gets delivered directly to those marked cells. This approach aims to attack the cancer cells more directly while ideally causing less harm to healthy cells.

The study has two main stages. In the first stage, a small group of patients will receive gradually increasing doses of TUB-040. This helps the study doctors find the highest dose that can be given safely without causing too many serious side effects. Once a safe dose range is found, the second stage will compare a couple of different doses within that range to figure out which dose works best for patients, balancing its effectiveness with any side effects.

النقاط الرئيسية

  • This study is for adults with advanced ovarian cancer or non-small cell lung cancer.
  • It's testing a new drug called TUB-040 that aims to target cancer cells.
  • The study has two parts: finding the safest dose and then the most effective dose.
  • Treatment is given through a drip every 3 weeks.
  • You must have already tried standard treatments.

من قد يكون مؤهلاً؟

To be considered for this study, you need to be at least 18 years old. Importantly, your cancer should not be treatable with standard methods that aim to cure it. You should also have already tried the usual treatments, and joining this study should not mean you miss out on any standard treatment that could still help you.

Doctors will also need to be able to measure your cancer on scans to see if the treatment is working. Your general health and fitness, as measured by a scale called ECOG, should be good (0 or 1). You should also be expected to live for more than 12 weeks, as assessed by the doctor.

There are also some requirements about your body's organ functions (like your liver and kidneys) being healthy enough, and any side effects from previous treatments (like chemotherapy or surgery) should have mostly gone away. Women who could become pregnant and men with partners who could become pregnant will need to use effective birth control during and for some time after the study.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 18 سنة أو أكثر؟
  2. Has your doctor said your cancer cannot be cured by standard treatments?
  3. Have you already tried the usual treatments for your cancer?
  4. Can your cancer be measured on scans?
  5. Is your general health reasonably good (ECOG score 0-1)?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you will receive the study drug, TUB-040, through a drip into your vein. This treatment will be given every three weeks. You will continue to receive the treatment for as long as it is helping you and your cancer is not getting worse, or until you experience side effects that make it necessary to stop.

Throughout the study, you will have regular visits to the hospital for check-ups, blood tests, and scans (like CT scans of your chest) to monitor your health and see how the treatment is affecting your cancer. You’ll also have lung function tests at the beginning. You will also be asked to provide samples of any tissue (from a previous biopsy) for research purposes. The total length of your participation will depend on how you respond to the treatment and whether you experience any side effects.

المخاطر والفوائد المحتملة

Taking part in early-stage clinical trials like this one means there's a chance the new treatment might help your cancer, especially if standard options haven't worked. However, new treatments can also have side effects, some of which might be serious or unexpected. The research team will carefully monitor you for any side effects and manage them as best they can. There's no guarantee the treatment will work for you. You are free to withdraw from the study at any time, for any reason, without it affecting your future medical care.

المواقع (21)

  • جامعة ألاباما في برمنغهام
    الرمز البريدي المؤكد
    برمنغهام، الولايات المتحدة· التوظيف
  • معهد وينشيب للسرطان بجامعة إيموري
    الرمز البريدي المؤكد
    أتلانتا، الولايات المتحدة· التوظيف
  • Dana Farber Cancer Institute (DFCI)
    الرمز البريدي المؤكد
    بوسطن، الولايات المتحدة· التوظيف
  • START New Jersey (Astera Cancer Center)
    الرمز البريدي المؤكد
    East Brunswick, United States· التوظيف
  • Mount Sinai
    الرمز البريدي المؤكد
    نيويورك، الولايات المتحدة· التوظيف
  • The Christ Hospital Physicians - Mt. Auburn
    الرمز البريدي المؤكد
    سينسيناتي، الولايات المتحدة· التوظيف
  • Ohio State University CRS
    الرمز البريدي المؤكد
    كولومبوس، الولايات المتحدة· التوظيف
  • مركز ستيفنسون للسرطان
    الرمز البريدي المؤكد
    مدينة أوكلاهوما، الولايات المتحدة· التوظيف
  • Asante Rogue Region al Medical Center
    الرمز البريدي المؤكد
    Medford, United States· التوظيف
  • START Dallas Fort Worth
    الرمز البريدي المؤكد
    فورت وورث، الولايات المتحدة· التوظيف
  • NEXT Oncology Dallas
    الرمز البريدي المؤكد
    Irving, United States· التوظيف
  • START Mountain Region
    الرمز البريدي المؤكد
    مدينة وادي الغرب، الولايات المتحدة· التوظيف

أسئلة شائعة

What does 'non-small cell lung cancer' mean?

It's the most common type of lung cancer, and this study focuses on that specific kind.

ما هو 'الاقتران بين الجسم المضاد والدواء'؟

It's a clever drug that combines a targeting part (like a homing missile) with a medicine, aiming to deliver the medicine directly to cancer cells.

What does 'exhausted the standard of care treatment' mean?

It means you've already tried the usual, established treatments for your cancer that doctors would normally recommend, and they haven't been as effective as hoped.

How will I know if the treatment is working?

The study team will use regular scans and other tests to see if your cancer is shrinking or being controlled.

هل يمكنني التوقف عن المشاركة في الدراسة في أي وقت؟

Yes, you are always free to leave the study at any time, for any reason, and it won't affect your future medical care.

كيفية معرفة المزيد

مركز معلومات الدراسات السريرية لشركة جيلياد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "FiH Study to Investigate Safety, PK and Efficacy of the NaPi… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.